Click Here for 5% Off Your First Aladdin Purchase!

BMS-986020 - 99%, high purity , Lysophosphatidic acid receptor Edg-2 antagonist, CAS No.1257213-50-5, Lysophosphatidic acid receptor Edg-2 antagonist

  • Moligand™
  • ≥99%
Item Number
B413030
Grouped product items
SKUSizeAvailabilityPrice Qty
B413030-5mg
5mg
In stock
$93.90
B413030-10mg
10mg
In stock
$147.90
B413030-25mg
25mg
In stock
$333.90
B413030-50mg
50mg
In stock
$444.90
B413030-100mg
100mg
In stock
$741.90

LPA Receptor Antagonists

View related series
LPA1 receptor Antagonist

Basic Description

SynonymsBMS-986020|1257213-50-5|AP-3152 free acid|Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]-|BMS 986020|38CTP01B4L|(R)-1-(4'-(3-Methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)
Specifications & PurityMoligand™, ≥99%
Biochemical and Physiological MechanismsBMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respective
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionLysophosphatidic acid receptor Edg-2 antagonist
Product Description

Information

BMS-986020 BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1) . BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).


Targets

LPA1 ; BSEP (Cell-free assay); MRP4 (Cell-free assay); MDR3 (Cell-free assay) ; 4.8 μM; 6.2 μM; 7.5 μM

Product Properties

ALogP5.3

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2D6 Tclin Cytochrome P450 2D6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C8 Tchem Cytochrome P450 2C8 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C19 Tchem Cytochrome P450 2C19 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2B6 Tchem Cytochrome P450 2B6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C9 Tchem Cytochrome P450 2C9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABCB4 Tbio Phosphatidylcholine translocator ABCB4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B1 Tchem Solute carrier organic anion transporter family member 1B1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

LPAR1 Tchem Lysophosphatidic acid receptor 1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABCC3 Tbio Canalicular multispecific organic anion transporter 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABCC4 Tchem Multidrug resistance-associated protein 4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABCB11 Tchem Bile salt export pump 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488201431
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488201431
IUPAC Name 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
INCHI InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1
InChi Key GQBRZBHEPUQRPL-LJQANCHMSA-N
Canonical SMILES CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
Isomeric SMILES CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
PubChem CID 49792850
Molecular Weight 482.53

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

10 results found

Lot NumberCertificate TypeDateItem
C2323320Certificate of AnalysisFeb 03, 2023 B413030
C2323323Certificate of AnalysisFeb 03, 2023 B413030
C2323327Certificate of AnalysisFeb 03, 2023 B413030
C2323348Certificate of AnalysisFeb 03, 2023 B413030
C2323377Certificate of AnalysisFeb 03, 2023 B413030
C2323384Certificate of AnalysisFeb 03, 2023 B413030
C2323450Certificate of AnalysisFeb 03, 2023 B413030
C2323462Certificate of AnalysisFeb 03, 2023 B413030
C2323763Certificate of AnalysisFeb 03, 2023 B413030
C2323989Certificate of AnalysisFeb 03, 2023 B413030

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 97 mg/mL (201.02 mM); Ethanol: 97 mg/mL (201.02 mM); Water: Insoluble;

Related Documents

References

1. Kihara Y, Mizuno H, Chun J.  (2015)  Lysophospholipid receptors in drug discovery..  Exp Cell Res,  333  (2): (171-7).  [PMID:25499971]
2. Palmer SM, Snyder L, Todd JL, Soule B, Christian R, Anstrom K, Luo Y, Gagnon R, Rosen G.  (2018)  Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis..  Chest,  154  (5): (1061-1069).  [PMID:30201408]

Solution Calculators